Mechanisms of nerve regeneration for drug-resistant epilepsy: scoping review protocol

Authors

  • Renato García-González Facultad de Medicina. Benemérita Universidad Autónoma de Puebla
  • Hugo Sandoval General Directorate. National Institute of Rehabilitation Luis Guillermo Ibarra Ibarra
  • Rakesh Mishra Department of Neurosurgery. Institute of Medical Sciences. Banaras Hindu University
  • Antonio Malvaso School of Medicine and Surgery, Vita-Salute San Raffaele University https://orcid.org/0000-0001-9691-0890
  • Christoper A. Alarcon-Ruiz Research Unit for the Generation and Synthesis of Health Evidence, Universidad San Ignacio de Loyola, Lima, Peru
  • Camilo Ríos Department of Neurochemistry. National Institute of Neurology and Neurosurgery Manuel Velasco Suárez
  • Iván Pérez-Neri Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez https://orcid.org/0000-0003-0190-7272

DOI:

https://doi.org/10.31157/an.v28i4.363

Keywords:

Epilepsy, Neurotrophic factor, Remyelination, Axonal growth, Regeneration

Abstract

Drug-resistant epilepsy is defined as “the failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules”, 30-40% of the patients with epilepsy present this condition decreasing their quality-of-life and increasing mortality risk. Current literature suggests therapeutic alternatives such as surgery or neurostimulation, but they show some limitations. Unless degenerative progression is prevented and the regulatory role of interneurons is restored, patients with drug-resistant epilepsy may not reach seizure freedom. Ongoing studies have developed techniques to manoeuvre signalling pathways for neural regeneration in the central nervous system, this is defined as “the regrowth or repair of nervous tissues, cells or cell products”. This scoping review protocol aims to evaluate the therapeutic potential of modulating nerve regeneration pathways for patients with drug-resistant epilepsy. Published studies (all publication types) will be retrieved from Web of Science, PubMed, Scopus, EBSCOhost, Ovid, and Google Scholar, from database inception to present. Studies describing patients or experimental models of drug-resistant epilepsy receiving any treatment modulating nerve regeneration pathways will be included. Studies in languages different than Spanish or English that could not be appropriately translated or whose full-text files could not be retrieved after all efforts made will be excluded. Studies will be assessed for eligibility by two independent researchers. Results will be presented in tables. A narrative synthesis will be provided.

References

1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482.
2. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-1077.
3. Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018;59(12):2179-2193.
4. Yoo JY, Panov F. Identification and Treatment of Drug-Resistant Epilepsy. CONTINUUM: Lifelong Learning in Neurology. 2019;25(2):362-380.
5. Sheng J, Liu S, Qin H, Li B, Zhang X. Drug-Resistant Epilepsy and Surgery. Curr Neuropharmacol. 2018;16(1):17-28.
6. Bernard C, Cossart R, Hirsch JC, Esclapez M, Ben-Ari Y. What is GABAergic inhibition? How is it modified in epilepsy. Epilepsia. 2000;41 Suppl 6:S90-5.
7. Wang X, So K-F, Xu X-M. Advances and challenges for neural regeneration research. Elsevier; 2015. p. 3-17.
8. Curcio M, Bradke F. Axon Regeneration in the Central Nervous System: Facing the Challenges from the Inside. Annu Rev Cell Dev Biol. 2018;34:495-521.
9. White AR, Tiwari D, MacLeod MC, Danzer SC, Gross C. PI3K isoform-selective inhibition in neuron-specific PTEN-deficient mice rescues molecular defects and reduces epilepsy-associated phenotypes. Neurobiol Dis. 2020;144:105026.
10. Jaworski T. Control of neuronal excitability by GSK-3beta: Epilepsy and beyond. Biochim Biophys Acta Mol Cell Res. 2020;1867(9):118745.
11. Toral-Rios D, Pichardo-Rojas PS, Alonso-Vanegas M, Campos-Peña V. GSK3β and Tau Protein in Alzheimer’s Disease and Epilepsy. Front Cell Neurosci. 2020;14:19.
12. Han CL, Ge M, Liu YP, Zhao XM, Wang KL, Chen N, Meng WJ, Hu W, Zhang JG, Li L, Meng FG. LncRNA H19 contributes to hippocampal glial cell activation via JAK/STAT signaling in a rat model of temporal lobe epilepsy. J Neuroinflammation. 2018;15(1):103.
13. Asghari Adib E, Smithson LJ, Collins CA. An axonal stress response pathway: degenerative and regenerative signaling by DLK. Curr Opin Neurobiol. 2018;53:110-119.
14. Arksey H, O’Malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology. 2005;8(1):19-32.
15. Pérez-Neri I, Diéguez-Campaa CE, Sandoval H, Chávez VA, Castro-Martínez E, Ríos C. Therapeutic potential of dehydroepiandrosterone for Parkinson’s disease: scoping review protocol. Arch Neurocien. 2022;in press
16. Rosca EC, Tudor R, Cornea A, Simu M. Parkinson’s Disease in Romania: A Scoping Review Protocol. Brain Sci. 2021;11(2):251.
17. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.
18. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I, Gøtzsche PC, Lasserson T, Tovey D, PRISMA FAG. PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med. 2013;10(4):e1001419.
19. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P G. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
20. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-473.
21. Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis. JBI; 2020
22. Polhemus AM, Bergquist R, Bosch de Basea M, Brittain G, Buttery SC, Chynkiamis N, Dalla Costa G, Delgado Ortiz L, Demeyer H, Emmert K, Garcia Aymerich J, Gassner H, Hansen C, Hopkinson N, Klucken J, Kluge F, Koch S, Leocani L, Maetzler W, Micó-Amigo ME, Mikolaizak AS, Piraino P, Salis F, Schlenstedt C, Schwickert L, Scott K, Sharrack B, Taraldsen K, Troosters T, Vereijken B, Vogiatzis I, Yarnall A, Mazza C, Becker C, Rochester L, Puhan MA, Frei A. Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review. BMJ Open. 2020;10(7):e038704.
23. Petticrew M, Roberts H. Systematic Reviews in the Social Sciences. Malden, MA: Wiley-Blackwell; 2005:352.
24. Shah SGS, Nogueras D, van Woerden H, Kiparoglou V. Effectiveness of digital technology interventions to reduce loneliness in adults: a protocol for a systematic review and meta-analysis. BMJ Open. 2019;9:e032455.
25. Strech D, Synofzik M, Marckmann G. Systematic reviews of empirical bioethics. J Med Ethics. 2008;34(6):472-477.
26. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147-153.
27. Tanila T, Tenhunen H, Hirvonen P. Value Mechanisms in the Implementation of Intelligent Patient Flow Management System - A Multiple Case Study. Stud Health Technol Inform. 2020;270:708-712.
28. Easy as PIE. Nursing. 1999;29(4):25.
29. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB, PRISMA-S G. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev. 2021;10(1):39.
30. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40-46.
31. editors. Improving efficiency and confidence in systematic literature searching. European Association for Health Information and Libraries (EAHIL).
32. Willcox MDP, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface, coronaviruses and COVID ‐19. Clin Exp Optom. 2020;103(4):418-424.
33. Takakusagi Y, Oike T, Shirai K, Sato H, Kano K, Shima S, Tsuchida K, Mizoguchi N, Serizawa I, Yoshida D, Kamada T, Katoh H. Validation of the Reliability of Machine Translation for a Medical Article From Japanese to English Using DeepL Translator. Cureus. 2021;13(9):e17778.
34. Pérez-Neri I, González-Aguilar A, Sandoval H, Pineda C, Ríos C. Therapeutic Potential of Ultrasound Neuromodulation in Decreasing Neuropathic Pain: Clinical and Experimental Evidence. Curr Neuropharmacol. 2021;19(3):334-348.
35. McKeown S, Mir ZM. Considerations for conducting systematic reviews: evaluating the performance of different methods for de-duplicating references. Syst Rev. 2021;10(1):38.
36. Bozada T, Borden J, Workman J, Del Cid M, Malinowski J, Luechtefeld T. Sysrev: A FAIR Platform for Data Curation and Systematic Evidence Review. Front Artif Intell. 2021;4:685298.
37. Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, Affengruber L, Stevens A. Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol. 2021;130:13-22.
38. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020‐compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Systematic Reviews. 2022;18(2)
39. O’Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, Evans T, Pardo Pardo J, Waters E, White H, Tugwell P. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol. 2014;67(1):56-64.
40. Usher R, Stapleton T. Approaches for assessing decision-making capacity in older adults: a scoping review protocol. JBI Evidence Synthesis. 2020;18(4):832-840.

Published

2022-08-22

How to Cite

García-González, R., Sandoval, H., Mishra, R., Malvaso, A., Alarcon-Ruiz, C. A., Ríos, C., & Pérez-Neri, I. (2022). Mechanisms of nerve regeneration for drug-resistant epilepsy: scoping review protocol. Archivos De Neurociencias, 28(4). https://doi.org/10.31157/an.v28i4.363

Issue

Section

Evidence synthesis